Key result
Pretransplant use of sacubitril-valsartan was associated with a significantly lower rate of post-transplant ECMO support compared to no use (13% vs. 27%; p=0.041).
Why the study?
The impact of the angiotensin receptor-neprilysin inhibitor sacubitril-valsartan on heart transplant recipients remains unknown.
Does pretransplant sacubitril-valsartan reduce post-transplant ECMO use in adult heart transplant recipients?
Cohort (n=152)
Does pretransplant sacubitril-valsartan reduce post-transplant ECMO use in adult heart transplant recipients?
Pretransplant use of sacubitril-valsartan in heart transplant candidates is associated with a significantly lower risk of requiring post-transplant ECMO support.
Answers are grounded in this paper and cite their sources.
Pretransplant sacubitril-valsartan was associated with lower post-transplant ECMO use; hypothesis-generating and should not yet change practice.
Background: Extracorporeal membrane oxygenation (ECMO) support after heart transplant is a risk factor for mortality in patients with severe graft dysfunction. Extensive studies have shown that angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril–valsartan has a significant effect on unloading and vascular remodeling in patients with heart failure; however, the impact of ARNIs on heart transplant recipients remains unknown. Methods: This observational, retrospective cohort study included 152 patients who underwent heart transplantation between January 2015 and April 2021. We excluded patients <18 years old and those who underwent re-transplantation or multiple organ transplantation. Patients were divided into two groups based on whether they received an ARNI for at least one month before transplant. The clinical data of recipients and donors from our institutional medical records and the China Organ Transplant Response System were interrogated. Results: In total, 67 patients (mean age, 49.6 years; 81% male) were treated with sacubitril/valsartan before transplant and included in the cohort. The total rate of post-transplant ECMO use was 21.1% (n = 32). Kaplan–Meier survival analysis showed a considerable increase in 6-month mortality in heart transplant recipients supported by ECMO (log-rank p < 0.001). The rate of ECMO use was significantly lower in patients treated with ARNIs than for those who were not (13% vs. 27%; p = 0.041). The multivariate analyses that included three models with different preset covariates demonstrated a lower risk of post-transplant ECMO support in patients receiving the ARNI (all p < 0.05). After propensity score matching, the results also suggested that ARNIs can be a protective factor against post-transplant ECMO support (p = 0.042). Conclusion: Pretransplant use of ARNI agents was associated with a lower risk of ECMO support after HT. Randomized controlled trials are warranted to confirm the effectiveness of ARNIs in improving post-transplant hemodynamics and reducing ECMO use in HT recipients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a cohort in Heart transplant recipients (n=152). Angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan vs. No pretransplant ARNI use was evaluated on Post-transplant ECMO use (p=0.041). Pretransplant use of sacubitril-valsartan was associated with a significantly lower rate of post-transplant ECMO support compared to no use (13% vs. 27%; p=0.041).
Synapse has enriched 10 related papers. Consider them for comparative context: